<DOC>
	<DOCNO>NCT00898456</DOCNO>
	<brief_summary>This research trial study multidrug resistance gene patient acute myeloid leukemia . Studying sample bone marrow blood patient cancer laboratory may help doctor learn change may occur deoxyribonucleic acid ( DNA ) identify biomarkers related cancer . It may also help doctor learn drug resistance patient respond treatment .</brief_summary>
	<brief_title>Multidrug Resistance Genes Patients With Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To investigate association common single nucleotide polymorphism ( SNPs ) haplotypes three multidrug resistance ( MDR ) gene treatment outcome clinical study . II . To assess effect ATP-binding cassette ( ABC ) B1 , ABCC1 , ABCG2 polymorphisms haplotype treatment outcome young patient enrol Cancer Leukemia Group B ( CALGB ) 9621 19808 . III . To assess effect ABCB1 , ABCC1 , ABCG2 polymorphisms haplotype treatment outcome old patient enrol CALGB 9720 . SECONDARY OBJECTIVES : I . To test hypothesis ABCB1 , ABCC1 , ABCG2 polymorphisms haplotype associate phosphoglycolate phosphatase ( Pgp ) , multidrug resistance protein 1 ( MRP-1 ) , ATP-binding cassette , sub-family G ( WHITE ) , member 2 ( Junior blood group ) ( BCRP ) function expression pre-treatment blast acute myeloid leukemia ( AML ) patient . II . To assess effect ABCB1 , ABCC1 , ABCG2 polymorphisms haplotype PGP , MRP-1 , BCRP function CALGB 9760 young patient enrol CALGB 9621 19808 . III . To assess effect ABCB1 , ABCC1 , ABCG2 polymorphisms haplotype PGP , MRP-1 , BCRP function CALGB 9760 old patient CALGB 9720 . IV . To conduct exploratory analysis association additional candidate gene relevant etoposide , cytarabine , daunorubicin chemotherapy response toxicity . OUTLINE : Leukemia blast cell obtain bone marrow aspirate peripheral blood diagnosis use study polymorphisms haplotypes ATP-binding cassette ( ABC ) B1 , ABCC1 , ABCG2 , candidate gene . Multidrug resistance ( MDR ) protein expression function also analyze use leukemia blast cell patient enrol CALGB-9760 . PROJECTED ACCRUAL : Tissue sample 600 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis acute myeloid leukemia Treated protocols CALGB9621 , CALGB9720 , CALGB19808 Registered mandatory companion Leukemia Tissue Bank Protocol CALGB9665 Registration another companion trial , CALGB9760 , ( Multidrug Resistance Studies Acute Leukemia ) allow PATIENT CHARACTERISTICS : Not specify PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
</DOC>